In an attempt to understand how SPHK inhibitors reduce the generation of venetoclax resistance in our in vitro system, we evaluated the expression of BCL-XL and MCL-1 in CLL cells, which are not targeted by venetoclax. Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.